197 related articles for article (PubMed ID: 6644317)
1. Clinical pharmacology of pyridostigmine and neostigmine in patients with myasthenia gravis.
Aquilonius SM; Eckernäs SA; Hartvig P; Lindström B; Osterman PO; Stålberg E
J Neurol Neurosurg Psychiatry; 1983 Oct; 46(10):929-35. PubMed ID: 6644317
[TBL] [Abstract][Full Text] [Related]
2. The effect of neostigmine on pyridostigmine bioavailability in myasthenic patients after oral administration.
Chan K; Davison SC; Dehghan A; Hyman N
Methods Find Exp Clin Pharmacol; 1981; 3(5):291-6. PubMed ID: 7329157
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacokinetics of cholinesterase inhibitors.
Aquilonius SM; Hartvig P
Clin Pharmacokinet; 1986; 11(3):236-49. PubMed ID: 3524957
[TBL] [Abstract][Full Text] [Related]
4. Steady state kinetics of pyridostigmine in myasthenia gravis.
Sørensen PS; Flachs H; Friis ML; Hvidberg EF; Paulson OB
Neurology; 1984 Aug; 34(8):1020-4. PubMed ID: 6540381
[TBL] [Abstract][Full Text] [Related]
5. The simultaneous monitoring of plasma levels of neostigmine and pyridostigmine in man.
Davison SC; Hyman N; Prentis RA; Dehghan A; Chan K
Methods Find Exp Clin Pharmacol; 1980 Apr; 2(2):77-82. PubMed ID: 7339332
[TBL] [Abstract][Full Text] [Related]
6. Neuromuscular function and plasma drug levels in pyridostigmine treatment of myasthenia gravis.
Breyer-Pfaff U; Schmezer A; Maier U; Brinkmann A; Schumm F
J Neurol Neurosurg Psychiatry; 1990 Jun; 53(6):502-6. PubMed ID: 2166138
[TBL] [Abstract][Full Text] [Related]
7. Plasma pyridostigmine levels in patients with myasthenia gravis.
Calvey TN; Chan K
Clin Pharmacol Ther; 1977 Feb; 21(2):187-93. PubMed ID: 837637
[TBL] [Abstract][Full Text] [Related]
8. Myasthenia gravis unmasked by imatinib.
Kopp CR; Jandial A; Mishra K; Sandal R; Malhotra P
Br J Haematol; 2019 Feb; 184(3):321. PubMed ID: 30203413
[No Abstract] [Full Text] [Related]
9. Plasma concentration of pyridostigmine and effects in myastenia gravis.
Chan K; Calvey TN
Clin Pharmacol Ther; 1977 Nov; 22(5 Pt 1):596-601. PubMed ID: 199393
[TBL] [Abstract][Full Text] [Related]
10. Prescription profile of pyridostigmine use in a population of patients with myasthenia gravis.
Machado-Alba JE; Calvo-Torres LF; Gaviria-Mendoza A; Augusto MejíA-Vélez C
Muscle Nerve; 2017 Dec; 56(6):1041-1046. PubMed ID: 28214292
[TBL] [Abstract][Full Text] [Related]
11. Determination of neostigmine and pyridostigmine in the urine of patients with myasthenia gravis.
NOWELL PT; SCOTT CA; WILSON A
Br J Pharmacol Chemother; 1962 Jun; 18(3):617-24. PubMed ID: 14480648
[TBL] [Abstract][Full Text] [Related]
12. Myasthenia gravis with features of the myasthenic syndrome. An investigation with electrophysiologic methods including single-fiber electromyography.
Schwartz MS; Stålberg E
Neurology; 1975 Jan; 25(1):80-4. PubMed ID: 1167410
[TBL] [Abstract][Full Text] [Related]
13. The effect of use of pyridostigmine and requirement of vecuronium in patients with myasthenia gravis.
Tripathi M; Kaushik S; Dubey P
J Postgrad Med; 2003; 49(4):311-4; discussion 314-5. PubMed ID: 14699228
[TBL] [Abstract][Full Text] [Related]
14. Pyridostigmine kinetics in healthy subjects and patients with myasthenia gravis.
Breyer-Pfaff U; Maier U; Brinkmann AM; Schumm F
Clin Pharmacol Ther; 1985 May; 37(5):495-501. PubMed ID: 3987173
[TBL] [Abstract][Full Text] [Related]
15. [Serum levels of pyridostigmine in myasthenia gravis: methods and clinical significance].
Schumm F; Gaertner HJ; Wiatr G; Dichgans J
Fortschr Neurol Psychiatr; 1985 Jun; 53(6):201-11. PubMed ID: 2991094
[TBL] [Abstract][Full Text] [Related]
16. Administering Neostigmine as a Subcutaneous Infusion: A Case Report of a Patient Dying With Myasthenia Gravis.
Hindmarsh J; Woods E; Lee M; Pickard J
J Palliat Care; 2020 Apr; 35(2):78-81. PubMed ID: 31411109
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of intranasal administration of neostigmine in myasthenic patients.
Sghirlanzoni A; Pareyson D; Benvenuti C; Cei G; Cosi V; Lombardi M; Nicora M; Ricciardi R; Cornelio F
J Neurol; 1992 Mar; 239(3):165-9. PubMed ID: 1573422
[TBL] [Abstract][Full Text] [Related]
18. The relationship of plasma levels of pyridostigmine to clinical effect in patients with myasthenia gravis.
Davison SC; Hyman NM; Dehghan A; Chan K
J Neurol Neurosurg Psychiatry; 1981 Dec; 44(12):1141-5. PubMed ID: 7334410
[TBL] [Abstract][Full Text] [Related]
19. Plasma pyridostigmine levels in myasthenia gravis.
White MC; De Silva P; Havard CW
Neurology; 1981 Feb; 31(2):145-50. PubMed ID: 7193298
[TBL] [Abstract][Full Text] [Related]
20. Anticholinesterase abuse in myasthenia gravis.
Munsat TL
J Neurol Sci; 1984 Apr; 64(1):5-10. PubMed ID: 6376715
[No Abstract] [Full Text] [Related]
[Next] [New Search]
